Full-Time

GMP Materials Management and Supply Chain Specialist

Materials Management, Supply Chain

Posted on 8/27/2025

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$56.73 - $78.85/hr

+ Bonus + Long-term Incentives (Equity) + Employee Stock Purchase Plan (ESPP)

San Carlos, CA, USA

Hybrid

Employees are required to be onsite at least three days per week (Tuesday–Thursday mandatory).

Category
Operations & Logistics (2)
,
Required Skills
Inventory Management
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
Requirements
  • 2–4 years of relevant GMP materials management, supply chain, or warehouse/distribution experience in the pharmaceutical or biotech industry (experience level determines title)
  • In-depth knowledge of pharmaceutical product shipment and warehouse operations in a GMP environment
  • Working knowledge of GMP, GDP, GCP, and relevant FDA guidelines
  • Technical skills in materials management with the ability to handle multiple priorities
  • Experience with international shipping logistics including generation of pro-forma and commercial invoices
  • Understanding of import/export requirements including incoterms and importer of record roles
  • Experience with cryogenic cold chain handling in a biopharmaceutical setting
  • Strong process orientation and attention to detail
  • Excellent verbal and written communication skills; able to collaborate across all levels of the organization
  • Highly self-motivated, adaptable to changing priorities, and comfortable in a fast-paced, small-company setting
  • Proficiency with MS Word, Excel, PowerPoint, and Outlook
Responsibilities
  • Perform receiving operations for both incoming materials and finished products
  • Schedule, prepare, and monitor shipments of final or intermediate products in compliance with GMP SOPs
  • Coordinate cold chain shipments from Adicet, ensuring proper packaging, documentation, and temperature control
  • Facilitate communications and address questions/concerns raised by partners such as clinical storage depots, distribution depots, and couriers
  • Collaborate with domestic depot and international depots to provide oversight for international drug supply shipments including creation of commercial invoices and ensuring all documents needed by courier and importer of record are established
  • Receive, inspect, release, and stock GMP materials, including cleanroom gowning, cleaning, and disinfection supplies
  • Prepare and kit materials for manufacturing in a timely and accurate manner
  • Maintain inventory management systems in compliance with standard warehouse practices (barcoding, FIFO, reorder triggers, manufacturing fill orders, etc.)
  • Monitor inventory and generate reports on quantities, lot status, and expiration dates for stakeholders
  • Investigate and resolve inventory discrepancies promptly
  • Collaborate with QA on the disposition of GMP raw materials
  • Ensure compliance with GMP, GDP, and applicable federal, state, and local regulations
  • Create, revise, and maintain SOPs related to materials management and supply chain processes
  • Drive continuous improvement in supply movement, warehouse optimization, and kitting processes
  • Complete day-to-day materials management tasks to ensure timely completion
  • Follow all safety procedures and support a culture of quality and compliance

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Prula-cel Phase 1 enrollment doubled to 20+ patients across seven autoimmune indications by end-2025.
  • ADI-212 regulatory filing expected H1 2026 for metastatic castration-resistant prostate cancer with Phase 1 Q4 2026.
  • $75M October 2025 raise extends cash runway into H2 2027, supporting multiple 2026 clinical data updates.

What critics are saying

  • Kyverna's KYV-101 achieved 100% complete remission in lupus nephritis, outperforming ADI-001 preliminary data.
  • BMS forba-cel demonstrates superior B-cell depletion and 14-month durability in SLE with greater commercialization resources.
  • Annual cash burn exceeds $200M; runway depletes Q2 2027 before pivotal trial data, risking financing necessity.

What makes Adicet Bio unique

  • First-in-class allogeneic gamma delta CAR T for autoimmune diseases with FDA Fast Track Designation.
  • Off-the-shelf manufacturing eliminates patient-specific cell collection, enabling rapid deployment versus autologous competitors.
  • Demonstrated no significant cytokine release syndrome or ICANS in clinical trials to date.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

2%
TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.

Stock Titan
Aug 4th, 2025
MaxCyte Signs Platform License Agreement with Adicet Bio

MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform.

Ochre Digi Media Pvt Ltd.
Feb 28th, 2025
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Systemic Sclerosis Treatment

Adicet Bio receives FDA Fast Track Designation for ADI-001 in systemic sclerosis treatment.

INACTIVE